Wealth Alliance Takes $241,000 Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Wealth Alliance bought a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIXFree Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 2,145 shares of the company’s stock, valued at approximately $241,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in NBIX. Headlands Technologies LLC increased its stake in shares of Neurocrine Biosciences by 36.4% during the 3rd quarter. Headlands Technologies LLC now owns 10,353 shares of the company’s stock worth $1,165,000 after purchasing an additional 2,762 shares during the last quarter. HighTower Advisors LLC lifted its position in shares of Neurocrine Biosciences by 9.5% in the third quarter. HighTower Advisors LLC now owns 7,233 shares of the company’s stock worth $821,000 after buying an additional 625 shares during the last quarter. Pathstone Family Office LLC bought a new stake in shares of Neurocrine Biosciences during the 3rd quarter worth about $323,000. Vanguard Personalized Indexing Management LLC increased its holdings in shares of Neurocrine Biosciences by 6.4% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 13,108 shares of the company’s stock valued at $1,475,000 after acquiring an additional 786 shares during the last quarter. Finally, Burney Co. increased its holdings in shares of Neurocrine Biosciences by 82.2% during the 3rd quarter. Burney Co. now owns 73,247 shares of the company’s stock valued at $8,240,000 after acquiring an additional 33,045 shares during the last quarter. 93.54% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

NBIX has been the subject of a number of recent analyst reports. Piper Sandler upped their target price on Neurocrine Biosciences from $95.00 to $100.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 1st. Deutsche Bank Aktiengesellschaft began coverage on shares of Neurocrine Biosciences in a report on Tuesday, December 12th. They set a “buy” rating and a $136.00 price objective for the company. Barclays lifted their target price on shares of Neurocrine Biosciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a report on Tuesday, January 23rd. Wells Fargo & Company upped their price target on shares of Neurocrine Biosciences from $127.00 to $140.00 and gave the company an “equal weight” rating in a report on Thursday, February 8th. Finally, StockNews.com raised Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 8th. Six equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $136.69.

View Our Latest Report on NBIX

Insider Transactions at Neurocrine Biosciences

In related news, CFO Matt Abernethy sold 1,280 shares of Neurocrine Biosciences stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $142.19, for a total transaction of $182,003.20. Following the transaction, the chief financial officer now owns 29,434 shares of the company’s stock, valued at approximately $4,185,220.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, insider Darin Lippoldt sold 10,919 shares of the business’s stock in a transaction that occurred on Monday, November 27th. The stock was sold at an average price of $112.27, for a total value of $1,225,876.13. Following the completion of the transaction, the insider now directly owns 35,882 shares in the company, valued at approximately $4,028,472.14. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Matt Abernethy sold 1,280 shares of the firm’s stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $142.19, for a total transaction of $182,003.20. Following the sale, the chief financial officer now owns 29,434 shares in the company, valued at $4,185,220.46. The disclosure for this sale can be found here. In the last ninety days, insiders sold 279,989 shares of company stock worth $36,339,235. 4.60% of the stock is currently owned by company insiders.

Neurocrine Biosciences Price Performance

NBIX opened at $130.43 on Tuesday. The firm has a 50 day simple moving average of $131.58 and a 200 day simple moving average of $117.72. The company has a market cap of $12.81 billion, a price-to-earnings ratio of 53.90, a price-to-earnings-growth ratio of 0.84 and a beta of 0.25. Neurocrine Biosciences, Inc. has a fifty-two week low of $89.04 and a fifty-two week high of $143.35.

Neurocrine Biosciences (NASDAQ:NBIXGet Free Report) last announced its quarterly earnings data on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, topping analysts’ consensus estimates of $1.13 by $0.31. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. The business had revenue of $515.20 million during the quarter, compared to analysts’ expectations of $518.52 million. During the same period in the previous year, the firm earned $0.88 earnings per share. The firm’s quarterly revenue was up 25.0% compared to the same quarter last year. As a group, analysts expect that Neurocrine Biosciences, Inc. will post 4.89 EPS for the current year.

Neurocrine Biosciences Company Profile

(Free Report)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas.

Featured Articles

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.